Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case––control study. (July 2008) - Subuh Surja, Anton A
Aripiprazole is primarily metabolized by the polymorphic CYP2D6. We genotyped four children (aged 6––15 years) who had developed extrapyramidal symptoms within 1 week of aripiprazole initiation or dose titration, and four matched children without extrapyramidal symptoms. All of the four children who developed extrapyramidal symptoms with aripiprazole had a dysfunctional CYP2D6 enzyme, based on genotype, and were categorized as either intermediate metabolizers (n = 2) or poor metabolizers (n = 2). By contrast, only two children from the control group had either of these phenotypes, and both were intermediate metabolizers. Children with CYP2D6 abnormalities may be at higher risk of aripiprazole-induced adverse drug reactions.